scispace - formally typeset
Journal ArticleDOI

Value of peritoneal cytology in potentially resectable pancreatic cancer.

Reads0
Chats0
TLDR
Peritoneal lavage cytology is used in the diagnosis and staging of various cancers and the clinical significance of positive cytology results in patients with pancreatic cancer is yet to be determined.
Abstract
Background Peritoneal lavage cytology (CY) is used in the diagnosis and staging of various cancers. The clinical significance of positive cytology results in patients with pancreatic cancer is yet to be determined. Methods Peritoneal washing samples were collected from consecutive patients with pancreatic cancer between July 1991 and December 2012. The correlations between cytology results, clinicopathological parameters and recurrence patterns were evaluated. The prognostic impact of CY status, regarding resectability and the effectiveness of adjuvant chemotherapy, were analysed. Results Of 523 included patients, 390 underwent resection. Patients with tumours at least 2 cm in diameter were more likely to have CY+ status than patients with tumours smaller than 2 cm (48 of 312 versus 3 of 78 respectively; P = 0·005) and there was a significant correlation between CY+ status and tumour invasion of the anterior pancreatic capsule (43 of 276 versus 8 of 113 with no invasion of the capsule; P = 0·030). Although the overall survival of patients with resected CY+ tumours was worse than that of patients with resected CY− tumours, it was significantly better than the survival of unresected patients regardless of CY status. Multivariable analysis of all patients who had pancreatectomy did not identify CY+ as an independent prognostic factor. Patients with CY+ tumours tended to develop peritoneal metastasis more often than those with CY− tumours, although not significantly so. The median survival time of 34 patients with resected CY+ tumours who received adjuvant chemotherapy was better than that of 17 patients who had surgery alone, although this was not statistically significant (15·3 versus 10·0 months; P = 0·057). Conclusion CY+ status is not clinically equivalent to gross peritoneal metastasis in patients with pancreatic cancer. Curative resection is still recommended regardless of CY status. Presented to the 98th Annual Clinical Congress of the American College of Surgeons, Chicago, Illinois, USA, October 2012

read more

Citations
More filters
Journal ArticleDOI

Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer

TL;DR: Distant metastasis is still frequently encountered on exploration for patients with potentially resectable PDAC, and younger age, male sex, larger tumor size, low ALT level and high CA19–9 level are independent predictors of unexpected distant metastasis on exploration.
Journal ArticleDOI

Pancreatic cancer with malignant ascites: clinical features and outcomes.

TL;DR: Although the prognosis of pancreatic cancer patients with MA remains poor, selected patients may be candidate for chemotherapy, regardless of the timing of appearance of MA.
Journal ArticleDOI

The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer

TL;DR: The Charlson age comorbidity index was a significant independent predictor of prognosis and compliance for postoperative adjuvant chemotherapy in the resected pancreatic cancer.
References
More filters
Book

Pancreatic Cancer

Journal ArticleDOI

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

TL;DR: A marked increase in the use of international datasets for more highly evidenced-based changes in staging, and the enhanced use of nonanatomic prognostic factors in defining the stage grouping are notable.
Journal ArticleDOI

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

TL;DR: It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Related Papers (5)